表紙
市場調查報告書

組蛋白去乙醯酵素4:開發平台評估(2020年下半年)

Histone Deacetylase 4 - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 954245
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
組蛋白去乙醯酵素4:開發平台評估(2020年下半年) Histone Deacetylase 4 - Pipeline Review, H2 2020
出版日期: 2020年07月31日內容資訊: 英文 70 Pages
簡介

本報告(H2 2020)涵蓋了有關組蛋白脫乙醯基酶4(組蛋白脫乙醯基酶A或HDAC4或EC 3.5.1.98)靶向治療的綜合訊息,包括適應症,發展階段,作用機理( MoA),給藥途徑(RoA)和分子類型,回顧了參與組蛋白去乙醯化酶4(組蛋白去乙醯化酶A或HDAC4或EC 3.5.1.98)針對性治療藥物開發的關鍵參與者,這些研究分別涉及活躍和休眠或已終止的項目。

本報告提供組蛋白去乙醯酵素4(組蛋白去乙醯酶4,HDAC4)市場的相關調查,開發中產品概要,治療評估,參與開發的企業,藥物簡介等資訊。

目錄

  • 目錄
    • 表格的清單
    • 圖的清單
  • 簡介
    • 調查範圍
  • 組蛋白去乙醯酵素4(組蛋白去乙醯酵素A或HDAC4或EC 3.5.1.98)-概要
    • 治療藥的開發
    • 各開發階段開發品
    • 各治療領域開發中產品
    • 各適應症開發中產品
    • 各企業開發中產品
    • 各大學、研究機關開發中產品
  • 治療評估
    • 各作用機制評估
    • 各給藥途徑評估
    • 各分子類型評估
  • 參與治療藥開發的企業
    • 4SC AG
    • MEI Pharma Inc
    • Mirati Therapeutics Inc
  • 藥物簡介
    • 活化心臟衰竭的HDAC4的基因治療-藥物簡介
      • 產品說明
      • 動作的機制
      • 研究開發的進展
      • MC-1568-藥物簡介
      • mocetinostat-藥物簡介
      • pracinostat-藥物簡介
      • resminostat-藥物簡介
    • 休止產品
    • 生產結束產品
    • 產品開發里程碑
      • 關注的新聞、新聞稿
    • 附錄
      • 調查手法
      • 調查範圍
      • 2次調查
      • 1次調查
      • 專家小組檢驗
      • 諮詢方式
    • 免責聲明
目錄
Product Code: GMDHC2541TDB

Summary:

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. It acts via the formation of large multiprotein complexes.

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology and Cardiovascular which include indications Congestive Heart Failure (Heart Failure), Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Gallbladder Cancer, Mycosis Fungoides, Myelodysplastic Syndrome, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Pulmonary Arterial Hypertension, Rhabdomyosarcoma and Sezary Syndrome.

The latest report Histone Deacetylase 4 - Pipeline Review, H2 2020, outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Overview
    • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
    • 4SC AG
    • MEI Pharma Inc
    • Mirati Therapeutics Inc
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Drug Profiles
    • Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MC-1568 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mocetinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pracinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • resminostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Dormant Products
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Discontinued Products
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by 4SC AG, H2 2020
  • Pipeline by MEI Pharma Inc, H2 2020
  • Pipeline by Mirati Therapeutics Inc, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Discontinued Products, H2 2020

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020